Which of the following is a first-line empiric therapy for outpatient CAP in a healthy adult without risk factors for drug resistance?

Prepare for the PANCE Pulmonology Exam. Use flashcards and multiple choice questions with helpful explanations to boost your knowledge and confidence. Get exam ready!

Multiple Choice

Which of the following is a first-line empiric therapy for outpatient CAP in a healthy adult without risk factors for drug resistance?

In outpatient CAP for a healthy adult with no risk factors for drug resistance, the goal is to use an antibiotic that covers both the usual bacteria that cause pneumonia and the atypical pathogens, while avoiding unnecessarily broad coverage. A macrolide (such as azithromycin or clarithromycin) or doxycycline fits this role well because each provides reliable activity against typical organisms like Streptococcus pneumoniae and also covers atypical pathogens such as Mycoplasma and Chlamydophila. This approach keeps the therapy effective but avoids the broader risks associated with fluoroquinolones. Levofloxacin monotherapy is a potent option, but it’s a fluoroquinolone with broader spectrum and more potential adverse effects, so it’s reserved for patients with asthma/COPD exacerbations, comorbidities, or prior treatment failures, rather than healthy individuals with no DR risk. Amoxicillin alone focuses on typical bacteria and misses atypicals, making it less ideal as first-line in this scenario. Therefore, the best choice reflects either a macrolide or doxycycline as first-line therapy for healthy outpatients with CAP.

In outpatient CAP for a healthy adult with no risk factors for drug resistance, the goal is to use an antibiotic that covers both the usual bacteria that cause pneumonia and the atypical pathogens, while avoiding unnecessarily broad coverage. A macrolide (such as azithromycin or clarithromycin) or doxycycline fits this role well because each provides reliable activity against typical organisms like Streptococcus pneumoniae and also covers atypical pathogens such as Mycoplasma and Chlamydophila. This approach keeps the therapy effective but avoids the broader risks associated with fluoroquinolones.

Levofloxacin monotherapy is a potent option, but it’s a fluoroquinolone with broader spectrum and more potential adverse effects, so it’s reserved for patients with asthma/COPD exacerbations, comorbidities, or prior treatment failures, rather than healthy individuals with no DR risk. Amoxicillin alone focuses on typical bacteria and misses atypicals, making it less ideal as first-line in this scenario. Therefore, the best choice reflects either a macrolide or doxycycline as first-line therapy for healthy outpatients with CAP.

More practice questions